Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional Analysis

Purpose: In a multi-institutional setting we studied the efficacy and safety outcomes at multiple high volume centers where collagenase Clostridium histolyticum is used to treat Peyronie's disease. Materials and Methods: We collected retrospective data on consecutive patients with Peyronie's disease who underwent treatment with collagenase C. histolyticum between April 2014 and March 2018 at a total of 5 institutions. Included in the study were 918 patients. Main outcomes of interest included the change in curvature after receiving collagenase C. histolyticum therapy and the frequency of serious treatment related adverse events. The 2-tailed paired Student t-test was used to compare continuous variables. Univariate and multivariate regression analyses were performed to assess predictors of the success of collagenase C. histolyticum therapy to improve curvature. Results: In the cohort of 918 patients curvature improved from a mean of 48.2 degrees before treatment to 32.9 degrees after treatment, a 30.1% improvement from baseline (p <0.0001). Of the men 68.7% had a 20% or greater improvement in curvature. In the 502 patients who completed 4 or more cycles curvature improved from a mean of 49.7 degrees before to 32.7 degrees after treatment, a 33% improvement from baseline (p <0.0001). Of these men 74.4% experienced a 20% or greater improvement in curvature. A complication of treatment developed in 9% of patients. The number of cycles of collagenase C. histolyticum received was predictive of curvature improvement (p <0.0001). Conclusions: This large multi-institutional analysis confirms the safety and efficacy of collagenase C. histolyticum therapy in men with Peyronie's disease. Intralesional collagenase C. histolyticum for Peyronie's disease according to the IMPRESS (Investigation of Maximal Peyronie's Reduction Efficacy and Safety Studies) trial protocol produced an improvement in penile curvature in men with Peyronie's disease with a low rate of complications.

[1]  M. Falcone,et al.  Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol , 2017, BJU international.

[2]  W. Hellstrom,et al.  Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute-Phase Peyronie's Disease. , 2017, The journal of sexual medicine.

[3]  N. Bennett,et al.  Peyronie's Disease and Injectable Collagenase Clostridium histolyticum: Safety, Efficacy, and Improvements in Subjective Symptoms. , 2016, Urology.

[4]  L. Trost,et al.  Restoration of Penile Function and Patient Satisfaction with Intralesional Collagenase Clostridium Histolyticum Injection for Peyronie's Disease. , 2016, The Journal of urology.

[5]  G. Kaufman,et al.  Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie's disease (PD) , 2015, BJU international.

[6]  I. Goldstein,et al.  Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. , 2013, The Journal of urology.

[7]  C. Nelson,et al.  Psychological impact of Peyronie's disease: a review. , 2013, The journal of sexual medicine.

[8]  Xiaolei Zhou,et al.  A Population-Based Study of Peyronie's Disease: Prevalence and Treatment Patterns in the United States , 2011, Advances in urology.

[9]  T. Lue,et al.  Risk factors for emotional and relationship problems in Peyronie's disease. , 2008, The journal of sexual medicine.

[10]  C. Nelson,et al.  The chronology of depression and distress in men with Peyronie's disease. , 2008, The journal of sexual medicine.

[11]  Stephen A Boorjian,et al.  Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. , 2004, The Journal of urology.

[12]  T. H. Klotz,et al.  Epidemiology of Peyronie's disease , 2002, International Journal of Impotence Research.

[13]  P. Grambsch,et al.  The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984. , 1991, The Journal of urology.

[14]  F. Dorey,et al.  The natural history of Peyronie's disease. , 1990, The Journal of urology.